26 Sep, 2023
Galecto Announces Plans to Explore Strategic Alternatives
BOSTON , Sept. 26, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced that it has completed a review of its business, including the status of its programs, resources,
31 Aug, 2023
Galecto to Present at Investor Conferences in September
BOSTON , Aug. 31, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer, today announced that Hans Schambye, M.D., Ph.D., President and Chief Executive
31 Jul, 2023
Galecto Reports Second Quarter Operating and Financial Results
BOSTON , July 31, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer, today announced its operating and financial results for the quarter ended June
20 Jun, 2023
Galecto Set to Join Russell Microcap® Index
BOSTON , June 20, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer, today announced that it is set to join the Russell Microcap Index at the
30 May, 2023
Galecto to Present at the Upcoming Jefferies Healthcare Conference
BOSTON , May 30, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer, today announced that Hans Schambye, M.D., Ph.D.
17 May, 2023
Galecto to Present Poster at Upcoming ATS 2023 International Conference
BOSTON , May 17, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer, today announced it will present a poster at the upcoming ATS 2023 International
28 Apr, 2023
Galecto Reports First Quarter Operating and Financial Results
BOSTON , April 28, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer, today announced its operating and financial results for the quarter ended